Primary biliary cholangitis and the narrowing gap towards optimal disease control

Area of Science:

• Hepatology
• Autoimmune Diseases
• Gastroenterology

Background:

• Primary biliary cholangitis (PBC) is a chronic, autoimmune, cholestatic liver disease.
• It can progress to biliary cirrhosis, significantly impacting quality and quantity of life.
• Current management often involves ursodeoxycholic acid and, in advanced cases, liver transplantation.

Purpose of the Study:

• To review current and emerging treatment strategies for PBC.
• To highlight the importance of early disease identification and risk stratification.
• To discuss challenges in evaluating PBC therapies and the need for real-world evidence.

Main Methods:

• Literature review of primary biliary cholangitis treatments.
• Analysis of emerging therapeutic targets beyond bile acid modulation.
• Discussion of clinical trial design challenges and real-world evidence generation.

Main Results:

• New therapeutic avenues are emerging, including farnesoid X receptor agonists, PPAR agonists, and ileal bile acid transporter inhibitors.
• Biochemical control (normal alkaline phosphatase, bilirubin) and symptom management (pruritus) are key outcomes.
• Generating real-world evidence is essential due to the long clinical course and difficulties in traditional study designs.

Conclusions:

• Primary biliary cholangitis requires multifaceted treatment approaches beyond ursodeoxycholic acid.
• Early identification of high-risk patients can optimize treatment benefits and prevent end-stage liver disease.
• Robust real-world evidence is critical for advancing the understanding and management of PBC.